A Milestone Meeting For US FDA: Vaccine Reviews After COVID

 
• By Michael McCaughan

The tandem reviews by a US FDA advisory committee of two RSV vaccine candidates from Pfizer and GSK is a milestone event for the agency. They are the first non-COVID vaccine BLAs to go to committee since the pandemic began – and the debut of the new vaccine office leadership at FDA.

Milestone
THE ROAD AHEAD FOR VRBPAC WILL INCLUDE NEW FACES AT OVRR AND LESS FOCUS ON COVID VACCINES. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers